Interferon alpha eye drops: Treatment of atypical lymphoid hyperplasia with secondary alopecia [3]

British Journal of Ophthalmology

Volumn 91, Issue 8, 2007, Pages 1085-1086

  Finger, Paul T ^a,b   Reichstein, D ^a  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b New York Eye Cancer Centre   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; EYE DROPS; STEROID;

ADULT; ALOPECIA; ANAMNESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; CONJUNCTIVA TUMOR; EYE BIOPSY; FEMALE; HUMAN; LETTER; LYMPHOID HYPERPLASIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SLIT LAMP; STEROID THERAPY; VISION TEST;

ADULT; ALOPECIA; ANGIOGENESIS INHIBITORS; CONJUNCTIVAL NEOPLASMS; FEMALE; HUMANS; HYPERPLASIA; INTERFERON-ALPHA; OPHTHALMIC SOLUTIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 34547216449     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.106930     Document Type: Letter

References (10)

1. Erickson BA, Harris GJ, Enke CA, et al. Periocular lymphoproliferative diseases: natural history, prognostic factors, and treatment. Radiology, 1992 Oct, 185:63-70.
2. Polito E, Leccisotti A. Prognosis of orbital lymphoid hyperplasia. Greafes Arch Clin Exp Ophthalmol 1996;234:150-4.
3. Coupland SE, Hellmich M, Auw-Haedrish C, et al. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol 2004;242:130-45.
4. Finger PT. Topical chemotherapy for malignant conjunctival and corneal neoplasia. Br J Ophthalmol 2006;90:807-9.
5. Boehm MD, Huang AJ. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology 2004;111:1755-61.
6. Esquenazi S, Fry CL, Holley E. Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b. Br J Ophthalmol 2005;89:1221.
7. Schechter BA, Schrier A, Nagler RS, et al. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Cornea 2002;21:6-11.
8. Guillot B, Blazquez L, Bessis D, et al. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 2004;208:49-54.
9. Taliani G, Biliotti E, Capanni M, et al. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis. C J Chemother 2005;17:212-4.
10. Wilson MW, Czechonska G, Finger PT, et al. Chemotherapy for eye cancer. Surv Ophthalmol 2001;45:416-44.